论文部分内容阅读
目的:探讨老年非小细胞肺癌(non-small cell lung cancer,NSCLC)患者抗癌治疗前血浆纤维蛋白原(fibrinogen,FIB)和D-二聚体(D-dimer)的预后意义。方法:测定97例肺癌患者(肺癌组)及36例健康体检者(对照组)血浆D-dimer、FIB水平并进行比较,并分析其与NSCLC临床病理因素之间关系及预后价值。结果:肺癌组血浆FIB、D-dimer水平高于健康对照组(P<0.05)。肺癌组FIB与TNM分期有关,D-dimer与淋巴结转移和TNM分期有关。单因素分析提示FIB、D-dimer、肿瘤大小、淋巴结转移、TNM分期与总体生存时间(overall survival,OS)和无进展生存时间(progression free survival,PFS)相关,而多因素分析仅提示D-dimer、FIB是老年NSCLC患者的独立危险预后因素。结论:检测老年NSCLC患者抗癌治疗前纤维蛋白原和D-二聚体可以指导预后,为肺癌个体化治疗提供一定的参考价值。
Objective: To investigate the prognostic significance of plasma fibrinogen (FIB) and D-dimer before anticancer therapy in elderly patients with non-small cell lung cancer (NSCLC). Methods: The plasma levels of D-dimer and FIB in 97 patients with lung cancer (lung cancer group) and 36 healthy controls (control group) were determined and compared with each other, and their relationship with the clinicopathologic factors and prognosis of NSCLC were analyzed. Results: The levels of plasma FIB and D-dimer in lung cancer group were higher than those in healthy control group (P <0.05). Lung cancer group FIB and TNM staging, D-dimer and lymph node metastasis and TNM staging. Univariate analysis showed that FIB, D-dimer, tumor size, lymph node metastasis, TNM stage were related to overall survival (OS) and progression free survival (PFS), while multivariate analysis only suggested that D- dimer, FIB is an independent risk prognostic factor for elderly NSCLC patients. Conclusion: The detection of fibrinogen and D-dimer before anticancer therapy in elderly patients with NSCLC can guide the prognosis and provide some reference value for individualized treatment of lung cancer.